U.S. markets open in 5 hours 55 minutes
  • S&P Futures

    4,159.50
    +12.75 (+0.31%)
     
  • Dow Futures

    32,857.00
    +100.00 (+0.31%)
     
  • Nasdaq Futures

    13,287.50
    +58.75 (+0.44%)
     
  • Russell 2000 Futures

    1,927.50
    +5.70 (+0.30%)
     
  • Crude Oil

    90.08
    +1.07 (+1.20%)
     
  • Gold

    1,794.10
    +2.90 (+0.16%)
     
  • Silver

    20.03
    +0.19 (+0.97%)
     
  • EUR/USD

    1.0207
    +0.0020 (+0.19%)
     
  • 10-Yr Bond

    2.8400
    0.0000 (0.00%)
     
  • Vix

    21.74
    +0.30 (+1.40%)
     
  • GBP/USD

    1.2112
    +0.0041 (+0.34%)
     
  • USD/JPY

    135.0810
    +0.1110 (+0.08%)
     
  • BTC-USD

    23,797.01
    +780.13 (+3.39%)
     
  • CMC Crypto 200

    552.63
    +17.40 (+3.25%)
     
  • FTSE 100

    7,477.04
    +37.30 (+0.50%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today

·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Amylyx Pharmaceuticals (NASDAQ: AMLX), a clinical-stage biopharma, is off to a good start this week. Amylyx's shares are responding positively to the news that the Food and Drug Administration (FDA) has decided to reconvene a panel of experts to discuss the pros and cons of the experimental amyotrophic lateral sclerosis (ALS) drug AMX0035. Earlier this year, this expert panel voted six to four against approving AMX0035 as a treatment for ALS.